lenvatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4942 417716-92-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • E-7080
  • E 7080
  • lenvatinib
  • lenvima
  • ER-203492-00
  • E7080
  • lenvatinib mesylate
  • lenvatinib mesilate
a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)
  • Molecular weight: 426.86
  • Formula: C21H19ClN4O4
  • CLOGP: 3.05
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 115.57
  • ALOGS: -4.84
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
18 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 26, 2015 PMDA Eisai Co., Ltd.
Feb. 13, 2015 FDA EISAI INC
May 28, 2015 EMA Eisai Europe Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertension 1274.04 24.88 768 12954 243510 56034835
Malignant neoplasm progression 1097.02 24.88 472 13250 73115 56205230
Proteinuria 716.42 24.88 236 13486 17334 56261011
Palmar-plantar erythrodysaesthesia syndrome 506.10 24.88 191 13531 20874 56257471
Hypothyroidism 496.23 24.88 223 13499 37973 56240372
Decreased appetite 483.54 24.88 410 13312 218821 56059524
Platelet count decreased 395.44 24.88 272 13450 106111 56172234
Diarrhoea 245.96 24.88 502 13220 638005 55640340
Hepatic encephalopathy 236.55 24.88 90 13632 10020 56268325
Immune-mediated hypothyroidism 173.50 24.88 31 13691 143 56278202
Blood pressure increased 165.59 24.88 190 13532 144986 56133359
Cholecystitis 137.05 24.88 68 13654 14367 56263978
Dysphonia 136.27 24.88 99 13623 41848 56236497
Drug ineffective 133.08 24.88 31 13691 918958 55359387
Malaise 115.15 24.88 267 13455 367593 55910752
Blood thyroid stimulating hormone increased 106.82 24.88 45 13677 6518 56271827
Hepatic function abnormal 106.44 24.88 79 13643 34479 56243866
Gastrointestinal perforation 98.97 24.88 35 13687 3164 56275181
Stomatitis 97.36 24.88 133 13589 120677 56157668
Tumour haemorrhage 94.54 24.88 28 13694 1436 56276909
Hyperthyroidism 92.68 24.88 51 13671 13301 56265044
Fistula 84.88 24.88 42 13680 8813 56269532
Rheumatoid arthritis 80.25 24.88 3 13719 382601 55895744
Pneumothorax 77.13 24.88 47 13675 14820 56263525
Pyrexia 75.00 24.88 248 13474 418525 55859820
Ascites 73.67 24.88 66 13656 37478 56240867
Tracheal fistula 65.53 24.88 11 13711 32 56278313
Fatigue 65.03 24.88 369 13353 788183 55490162
Renal impairment 63.67 24.88 88 13634 80625 56197720
Thrombocytopenia 62.56 24.88 116 13606 136108 56142237
Condition aggravated 62.46 24.88 6 13716 344892 55933453
Cerebral haemorrhage 55.54 24.88 50 13672 28556 56249789
Immune-mediated hepatic disorder 54.91 24.88 13 13709 276 56278069
Posterior reversible encephalopathy syndrome 54.83 24.88 39 13683 15921 56262424
Cardiac failure 53.81 24.88 82 13640 82011 56196334
Drug hypersensitivity 51.95 24.88 4 13718 275201 56003144
Dehydration 51.33 24.88 117 13605 158708 56119637
Hypersensitivity 50.52 24.88 3 13719 256405 56021940
Intestinal perforation 50.16 24.88 32 13690 10927 56267418
Protein urine present 48.76 24.88 25 13697 5651 56272694
Colitis 47.98 24.88 55 13667 41756 56236589
Weight decreased 46.97 24.88 147 13575 240567 56037778
Large intestine perforation 46.40 24.88 27 13695 7824 56270521
Oral pain 45.31 24.88 43 13679 26250 56252095
Cholecystitis acute 45.15 24.88 26 13696 7390 56270955
Nephrotic syndrome 44.53 24.88 23 13699 5277 56273068
Swelling 43.83 24.88 4 13718 239767 56038578
Arterial haemorrhage 43.58 24.88 16 13706 1609 56276736
Thyroid disorder 43.19 24.88 32 13690 13906 56264439
Immune-mediated hepatitis 42.15 24.88 14 13708 1047 56277298
Weight increased 41.54 24.88 4 13718 229699 56048646
Pain 40.61 24.88 62 13660 663122 55615223
Oesophageal fistula 40.30 24.88 9 13713 146 56278199
Infusion related reaction 39.52 24.88 3 13719 208928 56069417
Off label use 39.07 24.88 47 13675 556133 55722212
Myocarditis 38.41 24.88 25 13697 8833 56269512
Vomiting 38.11 24.88 229 13493 497999 55780346
Toxicity to various agents 37.87 24.88 5 13717 224559 56053786
Thyroiditis 36.52 24.88 15 13707 2037 56276308
Tracheal haemorrhage 34.53 24.88 8 13714 154 56278191
Female genital tract fistula 33.50 24.88 18 13704 4474 56273871
Epistaxis 33.16 24.88 59 13663 66964 56211381
Arthropathy 32.50 24.88 5 13717 200270 56078075
Hypertensive crisis 32.22 24.88 27 13695 14009 56264336
Hyponatraemia 31.59 24.88 74 13648 102065 56176280
Joint swelling 30.99 24.88 16 13706 289784 55988561
Peritonitis 30.81 24.88 28 13694 16174 56262171
Nausea 30.21 24.88 301 13421 763877 55514468
Drug intolerance 29.25 24.88 14 13708 264804 56013541
Fall 28.64 24.88 27 13695 357483 55920862
Eastern Cooperative Oncology Group performance status worsened 28.49 24.88 10 13712 883 56277462
Renal cancer 28.17 24.88 17 13705 5262 56273083
Sinusitis 27.72 24.88 7 13715 197574 56080771
Alopecia 27.45 24.88 19 13703 293439 55984906
Product dose omission issue 27.33 24.88 8 13714 204745 56073600
Taste disorder 27.21 24.88 21 13701 9694 56268651
Primary adrenal insufficiency 25.23 24.88 6 13716 130 56278215

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Decreased appetite 765.61 22.32 608 14434 152609 31529693
Hepatic encephalopathy 741.77 22.32 269 14773 13402 31668900
Malignant neoplasm progression 736.80 22.32 460 14582 78538 31603764
Proteinuria 560.16 22.32 232 14810 16531 31665771
Palmar-plantar erythrodysaesthesia syndrome 546.96 22.32 223 14819 15260 31667042
Hypertension 530.96 22.32 457 14585 127643 31554659
Diarrhoea 369.28 22.32 622 14420 351787 31330515
Hypothyroidism 278.02 22.32 146 14896 17801 31664501
Tumour haemorrhage 221.43 22.32 72 14970 2556 31679746
Liver carcinoma ruptured 183.54 22.32 36 15006 135 31682167
Fatigue 160.17 22.32 431 14611 334775 31347527
Dysphonia 142.61 22.32 100 14942 20491 31661811
Blood pressure increased 137.86 22.32 179 14863 79454 31602848
Malaise 132.41 22.32 264 14778 168247 31514055
Oesophageal varices haemorrhage 124.59 22.32 48 14994 2812 31679490
Ascites 112.64 22.32 117 14925 40896 31641406
Cholecystitis 105.85 22.32 63 14979 9754 31672548
Drug ineffective 103.54 22.32 30 15012 395543 31286759
Hepatic failure 98.35 22.32 98 14944 32604 31649698
Ammonia increased 94.95 22.32 44 14998 4083 31678219
Stomatitis 93.32 22.32 104 14938 39334 31642968
Hepatic function abnormal 87.89 22.32 103 14939 41119 31641183
Cholangitis 82.85 22.32 50 14992 7936 31674366
Pneumothorax 77.02 22.32 64 14978 16846 31665456
Blood bilirubin increased 75.23 22.32 88 14954 35048 31647254
Blood thyroid stimulating hormone increased 67.01 22.32 33 15009 3504 31678798
Dehydration 64.41 22.32 161 14881 118950 31563352
Oral pain 64.27 22.32 46 14996 9719 31672583
Tumour rupture 58.27 22.32 15 15027 226 31682076
Tracheal fistula 54.81 22.32 12 15030 85 31682217
Drug interaction 54.04 22.32 16 15026 208527 31473775
Toxicity to various agents 52.68 22.32 11 15031 181476 31500826
Condition aggravated 51.79 22.32 8 15034 164001 31518301
Epistaxis 50.45 22.32 91 14951 53616 31628686
Platelet count decreased 50.23 22.32 140 14902 110295 31572007
Off label use 48.75 22.32 56 14986 347218 31335084
Portal vein thrombosis 47.15 22.32 26 15016 3481 31678821
Weight decreased 45.74 22.32 173 14869 159779 31522523
Gastrointestinal perforation 43.60 22.32 25 15017 3607 31678695
Hyperammonaemia 41.92 22.32 29 15013 5804 31676498
Vomiting 41.74 22.32 213 14829 223760 31458542
Renal cancer 41.20 22.32 32 15010 7647 31674655
Cholecystitis acute 37.90 22.32 27 15015 5660 31676642
Immune-mediated hepatitis 35.16 22.32 17 15025 1733 31680569
Thyroiditis 34.75 22.32 18 15024 2125 31680177
Adrenal insufficiency 34.50 22.32 36 15006 12623 31669679
Interstitial lung disease 33.12 22.32 83 14959 61320 31620982
Tracheo-oesophageal fistula 32.75 22.32 11 15031 432 31681870
Completed suicide 32.47 22.32 3 15039 91511 31590791
Protein urine present 31.96 22.32 23 15019 4897 31677405
Pneumonitis 31.43 22.32 54 14988 30598 31651704
Taste disorder 31.30 22.32 24 15018 5626 31676676
Rhythm idioventricular 28.89 22.32 9 15033 277 31682025
Liver abscess 28.72 22.32 19 15023 3532 31678770
Nausea 28.06 22.32 245 14797 307702 31374600
Neutropenia 27.88 22.32 16 15026 140348 31541954
Arterial haemorrhage 25.85 22.32 11 15031 833 31681469
Protein induced by vitamin K absence or antagonist II increased 25.65 22.32 5 15037 18 31682284
Liver disorder 24.95 22.32 48 14994 29659 31652643
Haemobilia 23.70 22.32 8 15034 319 31681983
Cholangitis acute 23.22 22.32 10 15032 780 31681522
Nephrotic syndrome 22.92 22.32 22 15020 6981 31675321
Overdose 22.81 22.32 6 15036 84658 31597644

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1437.25 22.23 705 20322 121034 70786383
Hypertension 1394.34 22.23 940 20087 295093 70612324
Proteinuria 995.27 22.23 361 20666 29013 70878404
Decreased appetite 872.19 22.23 719 20308 304061 70603356
Palmar-plantar erythrodysaesthesia syndrome 803.03 22.23 311 20716 29936 70877481
Hepatic encephalopathy 671.86 22.23 251 20776 21867 70885550
Hypothyroidism 561.73 22.23 273 20754 45482 70861935
Diarrhoea 375.21 22.23 756 20271 782585 70124832
Tumour haemorrhage 294.25 22.23 87 20940 3635 70903782
Platelet count decreased 277.03 22.23 301 20726 177921 70729496
Cholecystitis 199.53 22.23 105 20922 20596 70886821
Drug ineffective 187.77 22.23 28 20999 939724 69967693
Malaise 168.97 22.23 386 20641 432546 70474871
Hepatic function abnormal 165.61 22.23 147 20880 67849 70839568
Pneumothorax 162.19 22.23 99 20928 25747 70881670
Dysphonia 152.16 22.23 123 20904 49977 70857440
Immune-mediated hypothyroidism 150.11 22.23 32 20995 334 70907083
Ascites 141.05 22.23 134 20893 67413 70840004
Liver carcinoma ruptured 135.86 22.23 26 21001 148 70907269
Blood pressure increased 128.46 22.23 213 20814 188304 70719113
Blood thyroid stimulating hormone increased 120.39 22.23 56 20971 8423 70898994
Oesophageal varices haemorrhage 114.74 22.23 43 20984 3760 70903657
Tracheal fistula 110.42 22.23 21 21006 115 70907302
Gastrointestinal perforation 94.81 22.23 42 20985 5639 70901778
Blood bilirubin increased 92.49 22.23 101 20926 59800 70847617
Condition aggravated 89.20 22.23 11 21016 427624 70479793
Dehydration 84.97 22.23 199 20828 225943 70681474
Fistula 82.18 22.23 47 20980 10834 70896583
Stomatitis 80.55 22.23 140 20887 128371 70779046
Cholecystitis acute 80.53 22.23 48 20979 11946 70895471
Toxicity to various agents 79.28 22.23 10 21017 382162 70525255
Immune-mediated hepatitis 74.25 22.23 29 20998 2837 70904580
Hyperthyroidism 73.27 22.23 55 20972 20036 70887381
Pyrexia 73.21 22.23 364 20663 606588 70300829
Tracheo-oesophageal fistula 71.37 22.23 19 21008 537 70906880
Fatigue 69.52 22.23 449 20578 823870 70083547
Hepatic failure 68.58 22.23 85 20942 57540 70849877
Arterial haemorrhage 68.17 22.23 26 21001 2385 70905032
Nephrotic syndrome 64.79 22.23 40 20987 10600 70896817
Cholangitis 64.25 22.23 41 20986 11508 70895909
Ammonia increased 62.55 22.23 34 20993 7104 70900313
Cerebral haemorrhage 60.19 22.23 77 20950 53787 70853630
Renal impairment 59.93 22.23 132 20895 143805 70763612
Large intestine perforation 59.28 22.23 41 20986 13154 70894263
Off label use 56.72 22.23 83 20944 742977 70164440
Weight increased 56.40 22.23 4 21023 242327 70665090
Vomiting 56.09 22.23 333 20694 592778 70314639
Hypersensitivity 55.86 22.23 3 21024 229809 70677608
Drug interaction 55.26 22.23 22 21005 381419 70525998
Oesophageal fistula 53.67 22.23 14 21013 365 70907052
Thyroiditis 52.20 22.23 25 21002 4011 70903406
Drug hypersensitivity 51.73 22.23 8 21019 262451 70644966
Posterior reversible encephalopathy syndrome 50.11 22.23 48 20979 24354 70883063
Intestinal perforation 49.96 22.23 40 20987 16004 70891413
Cardiac failure 49.20 22.23 122 20905 143419 70763998
Colitis 48.68 22.23 76 20951 63738 70843679
Hyperammonaemia 48.64 22.23 33 20994 10260 70897157
Portal vein thrombosis 48.26 22.23 26 21001 5336 70902081
Hypertensive crisis 47.55 22.23 42 20985 19220 70888197
Protein urine present 46.37 22.23 31 20996 9409 70898008
Pneumonitis 45.86 22.23 68 20959 54529 70852888
Weight decreased 45.21 22.23 197 20830 310291 70597126
Adrenal insufficiency 45.13 22.23 46 20981 25149 70882268
Pain 44.35 22.23 74 20953 628742 70278675
Infusion related reaction 43.90 22.23 4 21023 197530 70709887
Cerebral infarction 41.16 22.23 57 20970 42952 70864465
Fall 40.73 22.23 43 20984 444053 70463364
Immune-mediated hepatic disorder 40.72 22.23 14 21013 954 70906463
Epistaxis 40.32 22.23 92 20935 102535 70804882
Product dose omission issue 39.85 22.23 8 21019 217460 70689957
Sinusitis 38.76 22.23 3 21024 169192 70738225
Interstitial lung disease 38.02 22.23 91 20936 104594 70802823
Haemoptysis 37.47 22.23 60 20967 51392 70856025
Hyponatraemia 37.06 22.23 118 20909 159969 70747448
Primary adrenal insufficiency 36.40 22.23 9 21018 188 70907229
Drug intolerance 36.12 22.23 11 21016 225676 70681741
Upper gastrointestinal haemorrhage 34.86 22.23 49 20978 37428 70869989
Tumour rupture 34.69 22.23 10 21017 381 70907036
Abdominal pain 34.10 22.23 195 20832 341932 70565485
Small intestinal perforation 34.01 22.23 17 21010 2992 70904425
Tumour lysis syndrome 32.92 22.23 36 20991 21324 70886093
Joint swelling 32.90 22.23 17 21010 253194 70654223
Immune-mediated myocarditis 32.76 22.23 11 21016 697 70906720
Overdose 31.61 22.23 6 21021 169739 70737678
Arthropathy 30.89 22.23 4 21023 150053 70757364
Female genital tract fistula 30.62 22.23 16 21011 3087 70904330
Swelling 30.51 22.23 9 21018 188530 70718887
Eastern Cooperative Oncology Group performance status worsened 30.46 22.23 13 21014 1595 70905822
Pulmonary embolism 29.99 22.23 108 20919 155759 70751658
Treatment failure 29.29 22.23 4 21023 144138 70763279
Oesophageal perforation 29.26 22.23 12 21015 1332 70906085
Musculoskeletal stiffness 27.99 22.23 5 21022 147755 70759662
Insomnia 27.73 22.23 15 21012 217791 70689626
Rhythm idioventricular 27.62 22.23 9 21018 519 70906898
Duodenal perforation 27.49 22.23 13 21014 2027 70905390
Liver disorder 27.35 22.23 58 20969 61510 70845907
Nasopharyngitis 27.29 22.23 16 21011 222190 70685227
Depression 26.38 22.23 13 21014 198961 70708456
Cancer pain 26.36 22.23 17 21010 4857 70902560
Tracheal haemorrhage 25.87 22.23 9 21018 635 70906782
Cholangitis acute 25.47 22.23 11 21016 1389 70906028
Immune-mediated renal disorder 24.96 22.23 6 21021 111 70907306
Malignant pleural effusion 24.89 22.23 14 21013 3125 70904292
Injection site pain 24.53 22.23 3 21024 117616 70789801
Taste disorder 24.52 22.23 23 21004 11362 70896055
Pancreatitis 24.40 22.23 56 20971 62612 70844805
Urticaria 24.25 22.23 9 21018 163040 70744377
Liver abscess 24.22 22.23 17 21010 5582 70901835
Tumour pain 24.14 22.23 12 21015 2086 70905331
Oral pain 24.11 22.23 36 20991 29030 70878387
Peritonitis 24.02 22.23 34 20993 26125 70881292
Hyperhidrosis 23.77 22.23 5 21022 131581 70775836
Paraesthesia 23.45 22.23 7 21020 145530 70761887
Asthma 23.07 22.23 4 21023 120789 70786628
Hepatic rupture 22.74 22.23 5 21022 61 70907356
Amylase increased 22.72 22.23 21 21006 10187 70897230
Pneumonia aspiration 22.44 22.23 54 20973 62235 70845182

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000020000 Receptor Tyrosine Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:62434 ALK inhibitor
CHEBI has role CHEBI:63457 FGFR inhibitors
CHEBI has role CHEBI:65207 vascular endothelial growth factor receptor inhibitors
CHEBI has role CHEBI:71031 orphan drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Endometrial carcinoma progressing after chemotherapy indication 254878006 DOID:2871
Follicular thyroid carcinoma indication 255028004 DOID:3962
Papillary thyroid carcinoma indication 255029007 DOID:3969
Renal cell carcinoma indication 702391001 DOID:4450
Thymic carcinoma indication 722670005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.09 acidic
pKa2 12.74 acidic
pKa3 13.02 acidic
pKa4 4.67 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL 9006256 July 27, 2027 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL 9006256 July 27, 2027 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Feb. 13, 2022 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Feb. 13, 2022 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Sept. 17, 2022 TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Sept. 17, 2022 TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL July 21, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL July 21, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 10, 2024 LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 10, 2024 LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Dec. 19, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Dec. 19, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 15, 2025 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 15, 2025 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR Ki 8.82 CHEMBL DRUG LABEL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR IC50 7 SCIENTIFIC LITERATURE DRUG LABEL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 7.66 SCIENTIFIC LITERATURE DRUG LABEL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR IC50 8.40 SCIENTIFIC LITERATURE DRUG LABEL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR IC50 8.28 SCIENTIFIC LITERATURE DRUG LABEL
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 7.29 SCIENTIFIC LITERATURE DRUG LABEL
Fibroblast growth factor receptor 1 Kinase INHIBITOR IC50 7.34 SCIENTIFIC LITERATURE DRUG LABEL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.51 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 7.96 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 5.41 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 7.34 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 6.76 CHEMBL
MAP kinase-activated protein kinase 2 Kinase Kd 7.20 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 6.66 CHEMBL
Aurora kinase B Kinase Kd 5.75 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme Kd 5.82 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 5.65 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 5.54 CHEMBL
Ferrochelatase, mitochondrial Enzyme Kd 5.55 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase Kd 6.50 CHEMBL
Mitogen-activated protein kinase kinase kinase 6 Kinase Kd 5.80 CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR IC50 7.41 SCIENTIFIC LITERATURE
Epidermal growth factor receptor Kinase INHIBITOR IC50 5.19 SCIENTIFIC LITERATURE
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 6.24 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 5.42 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.88 CHEMBL
Breakpoint cluster region protein Kinase Kd 5.39 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 6.10 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 6.25 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.66 CHEMBL

External reference:

IDSource
EE083865G2 UNII
D09919 KEGG_DRUG
4034239 VUID
N0000191429 NUI
857890-39-2 SECONDARY_CAS_RN
4034239 VANDF
C2986924 UMLSCUI
CHEBI:85994 CHEBI
LEV PDB_CHEM_ID
CHEMBL1289601 ChEMBL_ID
9823820 PUBCHEM_CID
DB09078 DRUGBANK_ID
CHEMBL2105704 ChEMBL_ID
9361 INN_ID
C531958 MESH_SUPPLEMENTAL_RECORD_UI
7426 IUPHAR_LIGAND_ID
1603296 RXNORM
232716 MMSL
294829 MMSL
294831 MMSL
30895 MMSL
d08346 MMSL
015899 NDDF
015900 NDDF
714108002 SNOMEDCT_US
714109005 SNOMEDCT_US
735068004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-704 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-704 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-704 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-708 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-708 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-708 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-710 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-710 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-710 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-712 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-712 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-712 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-720 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-720 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-720 CAPSULE 10 mg ORAL NDA 32 sections